Welcome to our dedicated page for Merrimack Pharmaceuticals news (Ticker: $MACK), a resource for investors and traders seeking the latest updates and insights on Merrimack Pharmaceuticals stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Merrimack Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Merrimack Pharmaceuticals's position in the market.
Merrimack Pharmaceuticals announced its intention to voluntarily delist its common stock on NASDAQ, contingent upon stockholder approval of the Plan of Dissolution. The company plans to issue an initial liquidating cash dividend in the range of $14.92 to $15.15 per share, subject to approval. The record date for stockholders to receive the dividend is May 10, 2024, with the stock to go ex-dividend on May 15, 2024. If the Plan of Dissolution is not approved, regular trading will continue. The company urges investors to review the Proxy Statement filed with the SEC for more information.
